InvestorsHub Logo
Followers 145
Posts 27556
Boards Moderated 3
Alias Born 02/07/2004

Re: None

Friday, 12/30/2016 8:56:47 AM

Friday, December 30, 2016 8:56:47 AM

Post# of 3986
Protalix BioTherapeutics

Protalix BioTherapeutics Inc. (NYSEMKT: PLX) just finished its final patient enrollment for its Phase 2 clinical trial of AIR DNase (PRX-110) for the treatment of cystic fibrosis. Interim results are expected in the first week of January 2017, with the full results from this mid-stage trial coming before the end of the first quarter of 2017.

Protalix shares were last trading at $0.46 apiece. The stock has a consensus price target of $2.40 and a 52-week trading range of $0.26 to $1.04.

http://247wallst.com/healthcare-business/2016/12/30/7-key-fda-decisions-and-catalysts-expected-in-january-and-february/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PLX News